Literature DB >> 18490537

Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.

Jeffrey A Cutler1, Barry R Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18490537      PMCID： PMC2897820          DOI： 10.1161/CIRCULATIONAHA.107.709931

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  56 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?

Authors:  Jeffrey A Cutler
Journal:  Hypertension       Date:  2006-06-26       Impact factor: 10.190

3.  The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Authors:  Paula T Einhorn; Barry R Davis; Barry M Massie; William C Cushman; Linda B Piller; Lara M Simpson; Daniel Levy; Chuke E Nwachuku; Henry R Black
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

6.  Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies.

Authors:  W W Piegorsch; C R Weinberg; J A Taylor
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

7.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?

Authors:  Richard H Grimm; Barry R Davis; Linda B Piller; Jeffrey A Cutler; Karen L Margolis; Joshua Barzilay; Richard A Dart; James F Graumlich; Robert A Murden; Otelio S Randall
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738
View more
  13 in total

1.  Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

Authors:  Kwang Kon Koh; Michael J Quon; Seung Hwan Han; Yonghee Lee; Soo Jin Kim; Yesl Koh; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2008-12-06       Impact factor: 4.164

2.  β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant.

Authors:  Marcus Dörr; Carsten O Schmidt; Thomas Spielhagen; Alexa Bornhorst; Katharina Hentschel; Christina Franz; Klaus Empen; Thomas Kocher; Scott R Diehl; Heyo K Kroemer; Henry Völzke; Ralf Ewert; Stephan B Felix; Dieter Rosskopf
Journal:  Pharmacogenomics       Date:  2010-09       Impact factor: 2.533

Review 3.  Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

Authors:  Donna K Arnett; Steven A Claas
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

4.  Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.

Authors:  Randall S Stafford; L Kay Bartholomew; William C Cushman; Jeffrey A Cutler; Barry R Davis; Glenna Dawson; Paula T Einhorn; Curt D Furberg; Linda B Piller; Sara L Pressel; Paul K Whelton
Journal:  Arch Intern Med       Date:  2010-05-24

5.  Soluble (Pro)Renin Receptor as a Negative Regulator of NCC (Na+-Cl- Cotransporter) Activity.

Authors:  Chuanming Xu; Yanting Chen; Fei Wang; Shiying Xie; Tianxin Yang
Journal:  Hypertension       Date:  2021-09-08       Impact factor: 9.897

6.  ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.

Authors:  Jackson T Wright; Jeffrey L Probstfield; William C Cushman; Sara L Pressel; Jeffrey A Cutler; Barry R Davis; Paula T Einhorn; Mahboob Rahman; Paul K Whelton; Charles E Ford; L Julian Haywood; Karen L Margolis; Suzanne Oparil; Henry R Black; Michael H Alderman
Journal:  Arch Intern Med       Date:  2009-05-11

Review 7.  Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

Authors:  Kwang Kon Koh; Seung Hwan Han; Pyung Chun Oh; Eak Kyun Shin; Michael J Quon
Journal:  Atherosclerosis       Date:  2009-09-12       Impact factor: 5.162

8.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

9.  Guidelines for use of diuretics: a view from a member of JNC 7.

Authors:  Barry L Carter
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-11       Impact factor: 3.738

10.  Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective.

Authors:  Barry M Massie
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.